We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.52%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$449M
AUM Growth
+$34.2M
Cap. Flow
+$72.9M
Cap. Flow %
16.24%
Top 10 Hldgs %
46.73%
Holding
81
New
13
Increased
18
Reduced
10
Closed
8
Avg Time Held
1.6 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
1.6 years

Top Buys

Rank Stock Value
1
EXC icon
Exelon
EXC
+$28.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.85M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$9.77M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$9.45M
5
ONC icon
BeOne Medicines Ltd
ONC
+$6.75M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.1M
2
EXEL icon
Exelixis
EXEL
+$10.3M
3
GILD icon
Gilead Sciences
GILD
+$8.27M
4
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$4.64M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 97.78%
2 Utilities 2.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AMGN icon
1
Amgen
AMGN
$235B
$32.6M 7.26%
144,746
+26,446
+22% +$5.58M
2018 Q4
12 quarters
NBIX icon
2
Neurocrine Biosciences
NBIX
$13.9B
$23.8M 5.31%
280,000
-9,500
-3% -$874K
2017 Q3
17 quarters
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$31.3B
$21.7M 4.84%
128,000
+53,000
+71% +$9.85M
2017 Q3
17 quarters
INCY icon
4
Incyte
INCY
$23B
$20.9M 4.66%
285,000
+14,640
+5% +$987K
2016 Q4
20 quarters
GILD icon
5
Gilead Sciences
GILD
$195B
$20.5M 4.57%
282,784
-120,000
-30% -$8.27M
2016 Q4
20 quarters
BHVN icon
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$19.3M 4.3%
139,900
-36,500
-21% -$4.64M
2020 Q2
6 quarters
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$18.5M 4.13%
126,500
+28,000
+28% +$4.35M
2019 Q1
11 quarters
PTCT icon
8
PTC Therapeutics
PTCT
$5.09B
$17.9M 3.98%
449,000
– –
2019 Q1
11 quarters
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$17.5M 3.89%
113,200
+3,500
+3% +$586K
2017 Q1
19 quarters
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$129B
$17M 3.78%
77,222
– –
2016 Q4
20 quarters
ILMN icon
11
Illumina
ILMN
$40.5B
$14.3M 3.18%
38,550
+10,794
+39% +$4.09M
2021 Q3
1 quarter
TVTX icon
12
Travere Therapeutics
TVTX
$4.98B
$11.8M 2.63%
380,000
– –
2020 Q4
4 quarters
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$1.5B
$11.6M 2.59%
138,100
+35,000
+34% +$2.85M
2021 Q1
3 quarters
BIIB icon
14
Biogen
BIIB
$34.8B
$11.4M 2.54%
47,500
+22,000
+86% +$5.66M
2018 Q4
12 quarters
IONS icon
15
Ionis Pharmaceuticals
IONS
$7.33B
$10.8M 2.41%
355,088
+310,307
+693% +$9.77M
2017 Q1
19 quarters
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$10.8M 2.4%
99,873
-138,000
-58% -$15.1M
2016 Q4
20 quarters
HRMY icon
17
Harmony Biosciences
HRMY
$2.23B
$10.1M 2.24%
236,000
– –
2021 Q2
2 quarters
EXC icon
18
Exelon
EXC
$43.8B
$9.98M 2.22%
+766,241
New +$28.9M
2021 Q4
0 quarters
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$10.8B
$9.29M 2.07%
105,156
+50,000
+91% +$4.13M
2016 Q4
20 quarters
SUPN icon
20
Supernus Pharmaceuticals
SUPN
$2.3B
$8.68M 1.93%
297,500
– –
2021 Q2
2 quarters
CRSP icon
21
CRISPR Therapeutics
CRSP
$4.98B
$8.19M 1.83%
+108,200
New +$9.45M
2021 Q4
0 quarters
AUPH icon
22
Aurinia Pharmaceuticals
AUPH
$2.23B
$7.65M 1.7%
334,500
+211,000
+171% +$5M
2020 Q3
5 quarters
REGN icon
23
Regeneron Pharmaceuticals
REGN
$82B
$7.64M 1.7%
12,100
+4,400
+57% +$2.71M
2020 Q2
6 quarters
GH icon
24
Guardant Health
GH
$22.3B
$7.45M 1.66%
74,500
+38,000
+104% +$3.93M
2021 Q2
2 quarters
ITCI icon
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.92M 1.32%
113,456
+34,000
+43% +$1.43M
2020 Q1
7 quarters
1
2 3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2021 Portfolio in Review

As of Q4 2021, International Biotechnology Trust held 81 positions worth $449M, up 8.3% from $415M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust deployed $72.9M of net new capital in Q4 2021, opening 13 new positions and adding to 18 existing holdings. Its largest new stake was Exelon: 766,241 shares worth $9.98M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Utilities.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $15.1M trimmed.

  • International Biotechnology Trust's largest Q4 2021 buy was Exelon: 766,241 shares worth $9.98M.
  • International Biotechnology Trust added most to Alnylam Pharmaceuticals in Q4 2021, an estimated $9.85M increase.
  • International Biotechnology Trust's biggest Q4 2021 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $15.1M.
  • International Biotechnology Trust fully exited Exelixis in Q4 2021, selling an estimated $10.3M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $449M portfolio in Q4 2021.
  • International Biotechnology Trust opened 13 new positions and closed 8 in Q4 2021.
  • International Biotechnology Trust's portfolio value rose 8.3% quarter-over-quarter to $449M.

Based on International Biotechnology Trust's 13F filing for Q4 2021, filed 15 Feb 2022.